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Abstract
Introduction: Pure red cell aplasia due to anti-epoetin antibodies is a known complication of
epoetin therapy for anemia due to chronic kidney disease. This disease has not previously been well
described in the setting of therapy for chronic hepatitis C virus infection. While treatment for pure
red cell aplasia due to anti-epoetin antibodies is usually with immunosuppressive therapy such as
calcineurin inhibition, the safety of this treatment in chronic hepatitis C virus infection is unknown.
To date, little has been published on the efficacy of rituximab on pure red cell aplasia due to anti-
epoetin antibodies.
Case presentation: This report describes a 65-year-old Asian-American woman who developed
pure red cell aplasia from high titer neutralizing anti-epoetin antibodies after epoetin-alfa therapy
during ribavirin and peg-interferon treatment for chronic hepatitis C virus infection. We describe the
outcome of her treatment with rituximab. The reticulocyte count increased, and anti-epoetin antibody
titer decreased with a loss of neutralizing activity in vitro, leading to a reduction in blood transfusions,
and eventual resolution of anemia, without reactivation of hepatitis C virus.
Conclusion: The diagnosis of pure red cell aplasia from anti-epoetin antibodies should be
considered in patients undergoing therapy for chronic hepatitis C virus infection who develop severe
anemia after administration of erythropoietin or darbepoetin. Though it is currently an off-label
indication, rituximab is a therapeutic option for patients with pure red cell aplasia due to anti-epoetin
antibodies.
Introduction
Since the introduction of recombinant erythropoietin
(r-epoetin) in 1988, an epidemic of pure red cell aplasia
(PRCA) due to anti-epoetin antibodies has been identi-
fied, with a peak incidence in 2002. The vast majority of
patients had anemia from chronic kidney disease (CKD)
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Associations were identified between the development of
PRCA and subcutaneous versus intravenous administra-
tion, the brand of epoetin, substitution of albumin with
polysorbate 80 and glycine as the vehicle [2] and the use of
pre-filled syringes with uncoated versus rubber coated
plungers [3,4].
The major diagnostic criteria for PRCA due to anti-epoetin
antibodies include treatment with epoetin for at least
3 weeks, a red blood cell transfusion requirement of
approximately 1 unit per week to keep hemoglobin levels
stable, reticulocyte count less than 10 × 10
9/L and no
major drop in white blood cell or platelet counts. Bone
marrow biopsy documentation of PRCA and serum assay
for neutralizing anti-erythropoietin antibodies are recom-
mended for confirmation of the diagnosis [5].
Treatment of chronic hepatitis C virus (HCV) infection
with ribavirin and interferon commonly results in adverse
hematologic effects, including hemolytic anemia (riba-
virin) and pancytopenia from bone marrow suppression
(alfa-interferon). The use of r-epoetin for anemia in this
setting has been associated with an increase in hemoglo-
bin levels, higher doses of ribavirin administered and
improvement in quality-of-life scores in patients being
treated for HCV [6-8]. While r-epoetin is commonly used
to treat anemia associated with HCV therapy, only one
case report of a patient with HCV and r-epoetin-associated
PRCA has been published to date [9].
Case presentation
A 65-year-old Asian-American woman was diagnosed with
chronic hepatitis C (HCV), genotype 2 and was referred for
treatment of her HCV infection. Abdominal imaging
showed a nodular appearance of the liver and hypersplen-
ism with mild thrombocytopenia and leukopenia: base-
line white blood cell count 3.2-3.5 × 10
9/L, neutrophil
count 1.2-1.5 × 10
9/L, hemoglobin 13.5-14.0 g/dL and
platelet count 90-100 × 10
9/L. She was treated with peg-
interferon and ribavirin, but therapy was stopped after
3 weeks because of neutropenia and flu-like symptoms.
Peg-interferon and ribavirin were re-initiated 8 months
later with growth factor support: granulocyte-colony
stimulating factor (G-CSF, Neupogen
“) 300 μg subcuta-
neously once to twice weekly and epoetin-alfa (Procrit®)
40,000 units subcutaneously every 1 to 2 weeks. HCV viral
load was undetectable by week 4 of therapy. At week 14,
she developed severe pancytopenia, with a nadir absolute
neutrophil count of 0.4 × 10
9/L, hemoglobin 6.5 g/dL
and platelet count of 20 × 10
9/L despite continued use of
growth factors. Packed red blood cell (PRBC) and platelet
transfusions were initiated, and ribavirin was discontin-
ued. Peg-interferon was continued at a reduced dose
through week27,at which time it was stopped. The patient
continued to require intermittent transfusions between
weeks 14 and 27 of treatment despite continued therapy
with epoetin-alfa 40,000 units subcutaneously twice a
week. HCV RNA was undetectable at the end of treatment.
Two months after discontinuation of anti-HCV therapy,
the patient was referred to Hematology for persistent
anemia. At that time, she denied any bleeding or jaundice,
and her main symptoms were fatigue and dyspnea on
exertion. On physical examination, she had normal vital
signs, no jaundice, ecchymoses or petechiae, no lympha-
denopathy and palpable hepatosplenomegaly. Laboratory
examinations revealed: white blood cell count 4.0 × 10
9/
L, neutrophil count 1.6 × 10
9/L, hemoglobin 8.9 g/dL,
mean corpuscular volume 88 fL, platelet count 63 × 10
9/
L, reticulocyte count 2.6 × 10
9/L (normal range,
26-110 × 10
9/L) and an erythropoietin level of 34 mIU/
mL (normal range 4.1-19.5). A peripheral blood smear
showed a reduction in all three hematopoietic cell lines
but with normal cellular morphology. Her ferritin level
was 2981 μg/L and thyroid stimulating hormone (TSH),
vitamin B12 and folate levels were all normal. Lactate
dehydrogenase (LDH) was mildly elevated at 189 IU/L
(normal range 91-185) and the direct Coomb’s test was
negative.
Bone marrow biopsy showed 10% cellularity with
profound erythroid hypoplasia, normal myeloid matura-
tion and normal megakaryocytes (Figures 1 and 2). The
hypocellularity was thought to be due to prior interferon
therapy or possibly HCV infection (though the hepatitis C
Figure 1. Bone marrow aspirate. Bone marrow aspirate
showing hypocellularity (overall 10%), near absence of
erythroid precursors with full maturation of the myeloid
series and normal megakaryocytes.
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was felt to be due to hepatic cirrhosis and hypersplenism.
Given the clinical picture of severe anemia and near absent
erythroid precursors in the bone marrow, the patient was
initially thought to have ribavirin-induced PRCA, and she
received two doses of intravenous gammaglobulin (IVIG)
1 g/kg monthly for 2 months, without any hematologic
improvement. Analysis of the patient’s serum showed
IgG1 antibodies to epoetin alfa at a titer of 14.05 μg/mL,
which neutralized the biologic activity of epoetin in vitro.
This confirmed a diagnosis of PRCA due to anti-epoetin
antibodies. Epoetin-alfa was discontinued.
The patient then received rituximab 375 mg/m
2 intrave-
nously weekly for four doses with monthly IVIG 0.5 g/kg
for 4 months starting at the time of rituximab therapy.
Within 5 months, the reticulocyte count began to increase,
which corresponded to a decreasing trend in PRBC
transfusions (Figure 3). Eight months after treatment, she
againhadadropinherreticulocytecount.Theanti-epoetin
alfa antibody titer was 7.52 μg/mL and was no longer
neutralizing. She was retreated with rituximab at the same
dose and schedule as before and there appeared to be
another more transient reticulocyte count response, and
though this did not translate to a significant change in
PRBC transfusions initially, the anemia eventually
resolved. Her last blood transfusion occurred 27 months
after her initial rituximab course, and her hemoglobin
remains stable and normal, 14 months after her last
transfusion. The anti-epoetin alfa antibody titer at 37
months after her initial rituximab course was 3.19 μg/mL.
The HCV viral load continues to be undetectable and her
liver disease remains compensated.
Discussion
This case demonstrates the potential risk of PRCA due to
anti-epoetin antibodies from r-epoetin therapy in patients
treated for HCV. Rituximab is a humanized, murine
monoclonal antibody that targets the CD20 antigen,
leading to antibody-dependent, complement-dependent,
cell-mediated cytotoxicity and apoptosis [10]. Case reports
and case series describe the successful use of rituximab for
the treatment of lymphoproliferative disease-associated
PRCA, in association with response in the underlying
lymphoproliferative disease [11]. Rituximab has also been
reportedtoinduceresponsesinprimaryacquiredPRCA[12]
and in r-epoetin-induced PRCA in a patient with CKD [13].
Because the risk of HCV reactivation with standard
immunosuppressive therapy is uncertain, and because of
concern for the heightened risk of infectious complica-
tions due to the patient’s cirrhosis, this patient was treated
with rituximab rather than alkylating agents, calcineurin
inhibitors or corticosteroids. IVIG was administered
because of the possibility of increased risk of HCV
reactivation due to B-cell depletion and hypogammaglo-
bulinemia from rituximab therapy; however, there is no
published evidence to guide this management.
Most reports of patients with r-epoetin-associated PRCA
consist of CKD patients treated outside of the USA. These
reports show that spontaneous recovery is rare, but several
immunosuppressive treatments can lead to full hemato-
logic recovery and elimination of serum anti-epoetin
Figure 2. Bone marrow biopsy. Core biopsy showing
hypocellularity (overall 10%), near absence of erythroid
precursors with full maturation of the myeloid series and
normal megakaryocytes.
Figure 3. Reticulocyte and red cell transfusions during
rituximab therapy. Pattern of reticulocyte count and red cell
transfusions over time since the diagnosis of pure red cell
aplasia. Rituximab 375 mg/m
2 was given weekly × 4 weeks
during months 1 and 9 after diagnosis, as indicated by the
vertical arrows at the top of the figure.
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rituximab for this disease. A retrospective study examining
the outcomes of 47 patients with CKD and r-epoetin-
associated PRCA showed no recovery in the 10 patients
who stopped epoetin but did not undergo any other
therapy [14]. In contrast, 78% of the 37 who received
immunosuppressive therapy regained transfusion inde-
pendence. In 33 patients who had anti-epoetin antibody
levels assayed after treatment, recovery only occurred in
those who achieved undetectable antibody levels. All
six patients who underwent kidney transplantation had
resolution of PRCA. In those treated with immunosup-
pressive therapy alone, the highest response rates were in
patients treated with cyclophosphamide plus corticoster-
oids (7 out of 8 recovered), cyclosporine (4 out of 6),
corticosteroids with or without IVIG (10 out of 18) and
corticosteroids plus IVIG and plasma exchange (1 out of 1).
Recovery from PRCA occurred in only one of nine
patients treated with IVIG alone, and in neither of the
patients treated with a non-rituximab anti-CD20 mono-
clonal antibody (0 out of 1) or mycophenylate mofetil
(0 out of 1) [14].
A larger series looked at the outcomes of 170 patients
diagnosed with r-epoetin-associated PRCA between 1988
and 2004 [15]. Of the 89 patients who were treated with
immunosuppressive therapy but did not undergo renal
transplant, 49% achieved hematologic recovery (≤1 PRBC
transfusions a month, hemoglobin ≥8g/dL and reticulo-
cyte count >20 × 10
9/L), but only one became transfu-
sion-independent. Of the 33 patients rechallenged with
r-epoetin, 56% (and 89% of those with undetectable
antibodies) regained r-epoetin-responsiveness. Of the nine
patients with neutralizing assay results at the time of
rechallenge, all eight without neutralizing antibodies
regained r-epoetin-responsiveness, but not the one patient
with a positive result [15]. This suggests that even those
with detectable antibodies may respond to r-epoetin
administration, especially if the antibody is non-neutraliz-
ing. However, our patient remained anemic despite the
continued presence of an anti-epoetin antibody that does
not neutralize epoetin activity in vitro, possibly suggesting
continued neutralization of endogenous erythropoietin.
While this series did not report any successes with anti-
CD20 therapy, a single case report of a patient with CKD
and r-epoetin-associated PRCA describes erythropoietic
recovery following rituximab and rechallenge with
r-epoetin [13]. A patient with HCV and r-epoetin-
associated PRCA achieved hematologic recovery in 6 weeks
after starting danazol [9].
Conclusion
This case highlights the importance of considering PRCA
from anti-epoetin antibodies in patients treated for HCV
who develop severe anemia refractory to r-epoetin or
darbepoetin administration. This is a well established, but
uncommon, consequence of using r-epoetin for the
anemia of CKD. Some authors have raised the question
as to whether the immune modulatory effects of alpha-
interferon therapy might increase the risk of developing
anti-epoetin antibodies [9], however this remains spec-
ulative. Because the use of recombinant hematopoietic
growth factors can ameliorate the hematologic toxicity
associated with HCV therapy [6,7], r-epoetin therapy
should not be withheld from patients being treated for
hepatitis C because of the low, but real, risk of developing
PRCA.
Our patient demonstrated initially improved but incom-
plete erythropoiesis in response to rituximab, then
resolution of her anemia more than 2 years after initial
treatment, without HCV reactivation. It is not known if she
would have eventually achieved spontaneous recovery
without treatment, or whether initial depletion of the anti-
epoetin-antibody-producing B-cell clone contributed to its
eventual extinction.
Rituximab may be considered a therapeutic option in
patients with PRCA due to anti-epoetin antibodies;
however, the use of rituximab in this setting is outside
the scope of its FDA indications. When given to patients at
risk for hepatitis B or hepatitis C viral reactivation, caution
should be exercised due to the risk of viral reactivation in
lymphoma patients receiving rituximab.
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